Astra USA Naropin safety data includes 218 C-section, 220 labor and delivery patients.
Executive Summary
ASTRA USA NAROPIN DATA INCLUDE EIGHT C-SECTION, NINE L&D SAFETY STUDIES, which were presented at a Dec. 12 Anesthetic & Life Support Drugs Advisory Committee review of the neuromuscular blocker ropivacaine. Astra USA presented data from eight studies performed in 218 Cesarean section patients receiving doses up to 150 mg of ropivicaine .5% concentration and nine studies of 220 labor and delivery patients receiving .25% ropivacaine. "The Pink Sheet" (Dec. 18, 1995, p. 7) incorrectly reported that Naropin safety data for use in pregnant women were derived exclusively from animal studies.You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
Shire Hopes To Sow Future Deals With $50M Venture Fund
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: